Please note: This website has recently moved from www.health.gov to odphp.health.gov. www.health.gov is now the official website of ODPHP’s parent organization, the Office of the Assistant Secretary for Health (OASH). Please update your bookmarks for easy access to all our resources. 

Pharmacological treatment for psychotic depression

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: December 2021

In this Cochrane systematic review, researchers compared the clinical efficacy of pharmacological treatments for patients with acute psychotic depression to a placebo. They studied these treatments: 

  • Antidepressant monotherapy 
  • Antipsychotic monotherapy 
  • Mifepristone monotherapy 
  • Combination of an antidepressant plus an antipsychotic

Researchers also assessed whether differences in response to treatment in the current episode are related to non‐response to prior treatment.

Researchers found some evidence that combination therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or a placebo. They found limited evidence to assess treatment with an antidepressant alone or with an antipsychotic alone. Evidence to assess the efficacy of mifepristone is lacking.

Further, researchers pointed out that psychotic depression is heavily under‐studied, limiting confidence in these conclusions.

Read more about this resource

Objectives related to this resource (3)

Suggested Citation

1.

Kruizinga J, Liemburg E, Burger H, et al. (2021). Pharmacological treatment for psychotic depression. Retrieved from https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/full.